Skip to main content
. 2013 Jun 4;21(8):1517–1525. doi: 10.1038/mt.2013.114

Figure 2.

Figure 2

SapC-DOPS targets exposed phosphatidylserine on glioma cells in vitro and in vivo. (a) Quantification of the mean fluorescence of exposed PtdSer in a panel of glioblastoma multiforme (GBM) cell lines. (b) Percent survival of GBM cells 72 hours after treatment with SapC-DOPS (SapC 50 μmol/l). Data shown are mean values of percent surviving cells for low and high PtdSer-expressing cell lines. **P = 0.01. (c) Representative luminescent and fluorescence IVIS images of mice implanted subcutaneously with U87ΔEGFR-Luc cells incubated with lactadherin (Lact-C2), β-2-glycoprotein-1 (β2GP1), or PBS, after intravenous treatment with SapC-DOPS-CVM, respectively. CVM, CellVue Maroon; SapC-DOPS, Saposin C-dioleoylphosphatidylserine; PBS, phosphate-buffered saline; PtdSer, phosphatidylserine.